or Try an Advanced Search...

    Technical Analysis for SLRX - Salarius Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 2.21 -7.14% -0.17
    SLRX closed down 7.14 percent on Monday, July 1, 2024, on 1.59 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical SLRX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -7.14%
    Volume Surge Other -7.14%
    Outside Day Range Expansion -7.14%
    Wide Bands Range Expansion -7.14%
    Oversold Stochastic Weakness -7.14%
    Older End-of-Day Signals for SLRX ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 5 hours ago
    Down 5% about 5 hours ago
    Down 3% about 5 hours ago
    Fell Below Previous Day's Low about 5 hours ago
    Down 2 % about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SLRX Chart by TradingView
    Basic chart:

    Profile

    Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Solid Tumors Clinical Development Oncology Breast Cancer Prostate Cancer Ovarian Cancer Treatment Of Breast Cancer Sarcoma Advanced Solid Tumors

    Is SLRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 12 Salarius Pharmaceuticals to effect 1-for-8 reverse stock split to regain Nasdaq compliance
    Jun 12 Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
    Apr 2 SLRX Pursues Important Goal
    Mar 25 Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
    Mar 22 Salarius Pharmaceuticals GAAP EPS of -$3.84
    Mar 22 Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Jan 17 Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
    Jan 16 Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
    See more SLRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.48
    52 Week Low 2.1
    Average Volume 21,383
    200-Day Moving Average 4.73
    50-Day Moving Average 3.58
    20-Day Moving Average 3.08
    10-Day Moving Average 2.62
    Average True Range 0.37
    RSI (14) 13.04
    ADX 31.08
    +DI 17.08
    -DI 31.49
    Chandelier Exit (Long, 3 ATRs) 2.78
    Chandelier Exit (Short, 3 ATRs) 3.22
    Upper Bollinger Bands 4.14
    Lower Bollinger Band 2.01
    Percent B (%b) 0.09
    BandWidth 69.37
    MACD Line -0.39
    MACD Signal Line -0.31
    MACD Histogram -0.0808
    Fundamentals Value
    Market Cap 8.7 Million
    Num Shares 3.94 Million
    EPS -6.59
    Price-to-Earnings (P/E) Ratio -0.34
    Price-to-Sales 18.12
    Price-to-Book 0.37
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.63
    Resistance 3 (R3) 2.64 2.51 2.56
    Resistance 2 (R2) 2.51 2.40 2.51 2.54
    Resistance 1 (R1) 2.36 2.34 2.30 2.35 2.51
    Pivot Point 2.23 2.23 2.20 2.23 2.23
    Support 1 (S1) 2.08 2.12 2.02 2.07 1.91
    Support 2 (S2) 1.95 2.06 1.95 1.88
    Support 3 (S3) 1.80 1.95 1.86
    Support 4 (S4) 1.79